NAVLE Hematology & Immunology High-Yield Guide: Blood Disease Questions

NAVLE hematology questions appear in every species block on the exam. Anemia workup, coagulopathy, immune-mediated disease, and lymphoma are not confined to one section — they recur across canine, feline, equine, and large animal vignettes alike. A student who has mastered the CBC interpretation algorithm and the treatment logic for immune-mediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (ITP/IMT) is equipped to answer a substantial proportion of NAVLE clinical reasoning questions regardless of species.

This veterinary hematology NAVLE study guide consolidates the highest-yield concepts: step-by-step CBC analysis, anemia classification by MCV and MCHC, pathophysiology and treatment of the major immune-mediated blood diseases, coagulation disorders, lymphoma protocols, feline blood typing, and a review of hypersensitivity types. Work through each section, commit the tables to memory, and use the practice question links at the bottom to test your recall under exam conditions.

Step-by-Step CBC Interpretation Algorithm

When a NAVLE question presents a complete blood count, use a systematic approach so you do not miss secondary findings. A structured algorithm prevents errors and mirrors the clinical reasoning the examiners are testing.

Walking through this six-step algorithm on every hematology vignette ensures you do not anchor prematurely on the first abnormality and miss a concurrent finding that changes the diagnosis.

Anemia Classification: Regenerative vs. Non-Regenerative

The single most important decision in anemia workup is distinguishing regenerative from non-regenerative anemia. This determines whether the problem is outside the bone marrow (blood loss or hemolysis — regenerative) or within the marrow itself (non-regenerative). The red cell indices then narrow the morphological subtype.

Key NAVLE memory points on indices: a high MCV + low MCHC in a regenerative anemia reflects polychromatic macrocytes (young RBCs are large and poorly hemoglobinized). A low MCV + low MCHC in a non-regenerative picture points toward chronic iron deficiency — the most common cause is chronic gastrointestinal blood loss (hookworms in puppies, GI ulceration in adults).

IMHA: Immune-Mediated Hemolytic Anemia

NAVLE IMHA questions are among the most commonly tested immune-mediated disease scenarios. IMHA is the destruction of red blood cells by the patient's own immune system and is a classic example of a Type II hypersensitivity reaction (antibody-mediated cytotoxicity).

Pathophysiology and Key Findings

In warm-antibody IMHA — the most common form — IgG antibodies coat the RBC surface. Macrophages in the spleen recognize the Fc portion of the antibody and phagocytose the cell (extravascular hemolysis). When complement is activated fully, intravascular hemolysis occurs, producing hemoglobinemia and hemoglobinuria.

The pathognomonic finding on blood smear is spherocytes — uniformly small, dense red cells lacking central pallor, produced when macrophages nibble the antibody-coated RBC membrane. Spherocytes are diagnostic of IMHA in dogs; they are less reliable in cats because feline RBCs normally lack central pallor.

Additional findings include:

• Positive saline agglutination test — mix one drop of blood with two drops of saline on a slide; macroscopic clumping indicates autoagglutination and is virtually diagnostic
• Positive Coombs test (direct antiglobulin test) — detects antibody or complement on the RBC surface; useful when agglutination is absent but IMHA is suspected
• Regenerative anemia with polychromasia and elevated reticulocytes (unless the disease is peracute or concurrent immune-mediated red cell aplasia is present)
• Hyperbilirubinemia and bilirubinuria from RBC breakdown

IMHA Treatment

The cornerstone of treatment is immunosuppression:

• Prednisolone 2 mg/kg/day PO — first-line; taper over 3–6 months as PCV stabilizes
• Azathioprine (dogs only) — add when prednisolone alone is insufficient; never use azathioprine in cats — feline red blood cells lack the enzyme thiopurine methyltransferase and will develop severe bone marrow toxicity; use chlorambucil in cats instead
• Clopidogrel — antiplatelet therapy to reduce thromboembolic risk; pulmonary thromboembolism is the leading cause of death in dogs with IMHA
• Transfusion threshold: PCV <12% or clinical signs of decompensation (collapse, severe tachycardia, syncope); use packed red blood cells (pRBCs) or whole blood; crossmatch before transfusing even if first transfusion
• Leflunomide, mycophenolate mofetil, cyclosporine — second-line immunosuppressants for refractory cases

Always search for an underlying trigger: drugs (sulfonamides, methimazole), infections (Mycoplasma haemofelis, Babesia, Ehrlichia), neoplasia, or vaccine reactions. Secondary IMHA treatment must address the underlying cause.

ITP/IMT: Immune-Mediated Thrombocytopenia

Immune-mediated thrombocytopenia (also called ITP or IMT) is destruction of platelets by antibody (another Type II hypersensitivity reaction). It is the most common cause of severe thrombocytopenia in dogs.

Key diagnostic and clinical points:

• Platelet count <50,000/?L creates risk of spontaneous hemorrhage; counts <20,000/?L are critical
• Classic signs: petechiae (pinpoint mucosal hemorrhages) and ecchymoses (larger bruises), epistaxis, melena, hyphema
• Bone marrow evaluation shows normal to increased megakaryocytes (production is normal; destruction is peripheral) — this finding distinguishes ITP from aplasia or myelophthisis
• Coagulation times (PT and aPTT) are normal — distinguishes from DIC and coagulation factor deficiencies

Treatment:

• Prednisolone 2 mg/kg/day — first-line immunosuppression
• Vincristine (single dose 0.02 mg/kg IV) — stimulates rapid platelet release from megakaryocytes; use when platelet count is critically low; effect seen within 24–72 hours
• Azathioprine — second-line in dogs; never in cats
• IVIG (intravenous immunoglobulin) — saturates macrophage Fc receptors; use in refractory or life-threatening cases; expensive but effective
• Transfusion: platelet-rich plasma or platelet concentrate if active life-threatening hemorrhage; platelets are consumed rapidly in ITP so transfusion is mainly a bridge

Coagulopathy: Rodenticide, DIC, von Willebrand Disease, and Hemophilia

Coagulation disorders are highly testable on the NAVLE because they require interpreting specific laboratory tests and matching findings to mechanistic treatments. The table below is the foundation of coagulopathy NAVLE questions.

Anticoagulant Rodenticide Toxicosis

Second-generation anticoagulant rodenticides (brodifacoum, bromadiolone) inhibit vitamin K epoxide reductase, blocking the recycling of vitamin K. Without active vitamin K, the liver cannot carboxylate the vitamin K-dependent clotting factors: II, VII, IX, and X. Because factor VII has the shortest half-life (6 hours in dogs), the PT prolongs first — before the aPTT. This makes PT the most sensitive early screening test for rodenticide toxicosis.

Important NAVLE points:

• Baseline PT should be measured >24–48 hours post-ingestion to allow factor depletion; immediate PT may be normal
• Treatment: vitamin K1 (phytonadione) PO with a fatty meal for 4–6 weeks (second-generation rodenticides have very long half-lives); injectable vitamin K1 is reserved for critical bleeding; never use vitamin K3 (menadione) — causes Heinz body anemia in cats and horses
• Fresh frozen plasma (FFP) or whole blood provides immediate clotting factors in actively bleeding animals; vitamin K1 alone takes 6–12 hours to work
• A PT recheck 48–72 hours after stopping vitamin K confirms cure

DIC (Disseminated Intravascular Coagulation)

DIC is a paradoxical state of simultaneous pathological clotting and bleeding. It is always secondary to an underlying disease: sepsis, neoplasia (especially hemangiosarcoma), trauma, heat stroke, pancreatitis, snakebite, and obstetric emergencies.

Mechanisms: systemic activation of coagulation consumes clotting factors and platelets faster than they can be replaced. Fibrinolysis is simultaneously activated, generating FDPs that further impair platelet function. The result: micro-thrombosis in organs + hemorrhage from coagulation factor and platelet depletion.

Laboratory hallmarks of DIC (all must be interpreted together — no single test is definitive):

• Prolonged PT and aPTT — factor consumption
• Low fibrinogen — consumed
• Elevated FDPs and D-dimer — fibrinolysis activated
• Thrombocytopenia — platelet consumption
• Schistocytes on smear — RBCs sheared by fibrin strands in microvasculature

Treatment: address the underlying cause first. Supportive care with fresh frozen plasma (FFP) replaces consumed clotting factors. Platelet-rich plasma if severe thrombocytopenia. Heparin is controversial — may be used in early hypercoagulable phase to interrupt thrombus formation, but risks worsening hemorrhage.

Von Willebrand Disease (vWD)

vWD is the most common inherited bleeding disorder in dogs. Von Willebrand factor (vWF) is required for platelet adhesion to damaged endothelium (primary hemostasis) and also serves as a carrier for factor VIII.

Affected breeds: Doberman Pinscher, German Shepherd, Shetland Sheepdog, Scottish Terrier, Pembroke Welsh Corgi, and others. Type I vWD (quantitative deficiency) is most common, especially in Dobermans.

Characteristic laboratory profile: normal PT, normal aPTT, prolonged BMBT. The aPTT may be mildly prolonged in severe cases due to secondary factor VIII deficiency. Diagnosis is confirmed by vWF antigen assay.

Treatment and prevention:

• DDAVP (desmopressin) — releases stored vWF from endothelial cells; short-acting; useful pre-operatively in Type I disease
• Fresh frozen plasma or cryoprecipitate (enriched in vWF and factor VIII) — for acute bleeding or surgical patients
• Avoid NSAIDs — impair platelet function and worsen bleeding in vWD patients
• Genetic testing available; screen breeding animals

Hemophilia A and Hemophilia B

Both hemophilias are X-linked recessive disorders — males are predominantly affected; females are carriers.

• Hemophilia A — factor VIII deficiency; most common inherited coagulation factor deficiency; prolonged aPTT, normal PT; treatment: cryoprecipitate (highest concentration of factor VIII) or FFP
• Hemophilia B — factor IX deficiency (Christmas disease); prolonged aPTT, normal PT; treatment: FFP (cryoprecipitate is not enriched for factor IX)

Lymphoma: Multicentric, Mediastinal, and GI Forms

Lymphoma is the most common hematopoietic malignancy in dogs and cats. The NAVLE tests recognition of the major anatomic forms, typical patient profiles, and treatment protocols.

For NAVLE lymphoma questions in dogs, remember: B-cell multicentric lymphoma is the most common form, and the CHOP (Madison-Wisconsin 25-week) protocol is standard of care. T-cell lymphoma in dogs has a significantly worse prognosis — median survival approximately 6 months even with treatment. In cats, the distinction between low-grade GI lymphoma (excellent prognosis on chlorambucil + prednisolone) and high-grade GI lymphoma (poor prognosis, needs CHOP) is a classic exam discriminator.

Mast Cell Tumor and Systemic Mastocytosis

Mast cell tumors (MCTs) are the most common cutaneous tumor in dogs. On the NAVLE, questions may focus on the systemic effects of mast cell degranulation and bone marrow involvement.

Key high-yield points:

• Mast cells contain histamine and heparin granules; degranulation causes systemic histamine release, resulting in GI ulceration (via H2 receptor activation on parietal cells), hypotension, and coagulopathy
• Darier's sign — urticaria and local redness on palpation of the tumor mass
• Always give H1 blockers (diphenhydramine) and H2 blockers (famotidine, ranitidine) before surgical manipulation or biopsy of suspected MCTs
• Systemic mastocytosis involves bone marrow, spleen, and liver; buffy coat smear may show circulating mast cells; associated with visceral organ involvement and grave prognosis
• Grading: Patnaik grade I–III or Kiupel two-tier (low vs. high grade); high-grade histology predicts systemic spread
• Treatment: surgery (wide margins), toceranib (Palladia) or masitinib for c-KIT mutation-positive MCTs; corticosteroids for systemic disease

Blood Transfusion Medicine

Blood transfusion compatibility is a predictable NAVLE topic. The exam tests species-specific blood typing systems and the consequences of incompatible transfusions.

General principles:

• Crossmatching should always be performed before transfusion, even if it is the patient's first transfusion (sensitization can occur from pregnancy or prior exposure)
• Major crossmatch: donor RBCs + recipient serum — tests for recipient antibodies against donor RBCs (the most dangerous direction)
• Minor crossmatch: donor plasma + recipient RBCs — tests for donor antibodies against recipient RBCs
• Transfusion reactions: acute hemolytic (fever, hemoglobinemia, hemoglobinuria), febrile non-hemolytic, allergic (urticaria, vomiting), volume overload (TACO), transfusion-associated acute lung injury (TRALI)
• Stored pRBCs: refrigerated up to 35 days (CPDA-1 anticoagulant); fresh whole blood preferred for coagulopathies

Feline Blood Groups: Type A, B, and AB

Feline blood typing is a perennial NAVLE immune disease question. Cats have naturally occurring alloantibodies against blood group antigens they lack — unlike dogs, which must be sensitized first.

Key facts:

• Type A — most common; >90% of domestic cats in the United States; weak anti-B antibodies
• Type B — minority; some pure breeds are over-represented: Birman, British Shorthair, Devon Rex, Scottish Fold, Exotic Shorthair, Ragdoll; strong anti-A antibodies (high titer, highly hemolytic)
• Type AB — very rare; universal recipient; no alloantibodies

Neonatal isoerythrolysis (NI) is a classic NAVLE question:

• Occurs when a Type B queen is bred to a Type A tom
• Type A or AB kittens nurse colostrum containing the queen's high-titer anti-A antibodies
• Absorbed anti-A antibodies destroy the kittens' Type A RBCs — hemolytic anemia, hemoglobinuria ("red urine"), rapid death within 24–72 hours
• Prevention: remove Type A kittens from a Type B queen for the first 24 hours (until passive antibody transfer window closes); foster or hand-feed; reintroduce after 24 hours once gut has closed to antibody absorption
• Blood type both parents before breeding when using Type B breeds

For transfusion in cats: never give Type A blood to a Type B cat — the recipient's strong anti-A antibodies cause fatal acute hemolytic transfusion reaction within minutes. Even small volumes (1 mL) can be lethal.

Vaccination and Immunology: Hypersensitivity Types I–IV

Immunology on the NAVLE focuses on hypersensitivity classification and vaccination principles. The four hypersensitivity types (Gell and Coombs classification) are directly testable.

Vaccination high-yield points for the NAVLE:

• Core vaccines (dogs): CDV (distemper), CPV-2 (parvovirus), CAV-2 (adenovirus/hepatitis), rabies
• Core vaccines (cats): FPV (panleukopenia), FHV-1 (herpesvirus), FCV (calicivirus), rabies
• Non-core examples (dogs): Bordetella, Leptospira, Lyme, canine influenza (CIV)
• Non-core examples (cats): FeLV (recommended for outdoor/at-risk cats), FIV, Chlamydophila
• Feline injection-site sarcomas (FISS): most associated with FeLV vaccine and rabies vaccine; administer rabies vaccine in right rear limb distal to stifle; FeLV in left rear limb distal to stifle; other vaccines in right shoulder area — consistent anatomic sites allow identification of the vaccine responsible if sarcoma develops
• Modified live vaccines (MLV) are contraindicated in pregnant animals and severely immunosuppressed patients

Frequently Asked Questions: NAVLE Hematology and Immune Disease

What is the reticulocyte threshold for regenerative anemia in dogs vs. cats?

In dogs, an absolute reticulocyte count >80,000/?L indicates a regenerative response. In cats, the threshold is >50,000/?L using aggregate reticulocytes (the immature, clumped form). Punctate reticulocytes persist in cat blood for up to 10 weeks and are not counted for assessing acute regenerative response.

Why can't cats receive azathioprine for IMHA treatment?

Cats lack sufficient activity of thiopurine methyltransferase (TPMT), the enzyme that inactivates azathioprine's active metabolites. This enzyme deficiency causes accumulation of cytotoxic thioguanine nucleotides, resulting in severe myelosuppression, hepatotoxicity, and GI toxicity in cats. Chlorambucil is used instead for feline immune-mediated disease requiring a second immunosuppressant.

Why does anticoagulant rodenticide toxicosis prolong PT before aPTT?

Factor VII is the only clotting factor exclusively in the extrinsic pathway and has the shortest half-life (approximately 6 hours in dogs). As vitamin K-dependent synthesis is blocked, Factor VII is depleted first, prolonging the PT before the other vitamin K-dependent factors (II, IX, X) are depleted enough to prolong the aPTT. This makes PT the earliest and most sensitive laboratory indicator of rodenticide toxicosis.

What distinguishes low-grade from high-grade GI lymphoma in cats on the NAVLE?

Low-grade (small cell) GI lymphoma is the most common feline lymphoma overall. It affects older cats, is FeLV-negative, and responds excellently to oral chlorambucil + prednisolone with a median survival of 2 or more years. High-grade (large cell) GI lymphoma has a grave prognosis despite CHOP chemotherapy (median survival 3–4 months). Cytology or histopathology is required to distinguish the two — fine-needle aspirate may be insufficient; full-thickness biopsy is often needed.

What is neonatal isoerythrolysis and how is it prevented?

Neonatal isoerythrolysis (NI) in cats occurs when a Type B queen breeds with a Type A tom and produces Type A kittens. The Type B queen's colostrum contains high-titer anti-A antibodies. Type A kittens absorb these antibodies through the gut during the first 12–16 hours of life, causing acute hemolytic anemia, hemoglobinuria, icterus, and death. Prevention requires blood-typing both parents before breeding or removing Type A and AB kittens from a Type B queen for the first 24 hours of life and providing alternative colostrum.

What are the four types of hypersensitivity and a clinical example of each?

Type I (IgE-mediated): anaphylaxis, atopy. Type II (antibody-mediated cytotoxicity): IMHA, ITP. Type III (immune complex): glomerulonephritis, systemic lupus erythematosus. Type IV (cell-mediated, delayed): contact hypersensitivity, tuberculin skin test, granulomatous disease.

Related NAVLE Study Guides

• NAVLE Exam Complete Guide — full blueprint, strategy, and study timeline
• NAVLE Canine High-Yield Guide — top-tested dog diseases and differentials
• NAVLE Feline High-Yield Guide — cat-specific pharmacology, diseases, and pitfalls
• NAVLE Diagnostics High-Yield Guide — lab interpretation, imaging, and diagnostic algorithms